HOME >> MEDICINE >> NEWS
Acrux reports progress in development of Testosterone MD-Lotion(R) for men

Acrux Limited (ASX: ACR), the Australian pharmaceutical company which specialises in administering drugs through the skin, today announced positive results from two more clinical studies of its Testosterone MD-Lotion treatment for testosterone deficiency in men, which is associated with a number of symptoms including lethargy, depression and reduced libido. Both studies were conducted at the Centre for Clinical Studies, Melbourne, with Professor Susan Davis supervising as Principal Investigator.

The studies compared blood levels of testosterone in healthy volunteers. The aim of the first study was to compare two different formulations of Testosterone MD Lotion, and the aim of the second study was to compare two different application sites.

The results of the first study showed that both formulations provided similar blood levels, providing options for continued development of either formulation. In the second study, there was a significant difference in absorption between the two different application sites, providing important information for the design of the remaining clinical studies in men.

In both studies, the lotion was well tolerated, with no application site reactions noted, and no serious adverse events recorded. Full details of the studies are presented in Appendix 1.

Acrux's development of Testosterone MD Lotion is continuing, with further studies to commence shortly to confirm the doses required to maintain testosterone blood levels in the target range for effective treatment.

Acrux CEO and Managing Director, Dr Igor Gonda said: "We believe our fast drying, no-touch metered dose lotion has significant competitive advantage over the existing products in this growing market. The remaining trials suit our expertise and require moderate investment, so in line with our financial plans we intend to complete them ourselves before choosing the best option for sales and marketing".

The remaining development prog
'"/>

Contact: Igor Gonda
61-383-790-100
Research Australia
7-Sep-2005


Page: 1 2

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux and Oreganon further expand their collaboration
3. Acrux granted first grant in Europe, triggering payment from Lilly
4. Acrux patent portfolio advances in USA
5. Acrux acquires rights to commercialise worlds first contraceptive spray
6. Four new us patents granted to Acrux for transdermal drug delivery
7. New study reports hotel guests at risk from carbon monoxide poisoning
8. MIT reports key pathway in synaptic plasticity
9. ENDEAVOR III Trial reports key findings on new-generation stent
10. New study reports improved treatment and reduced mortality for patients with heart failure
11. Study reports changing to a low-fat diet can induce stress

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
Breaking Medicine Technology:
Cached News: